Exclusive: AstraZeneca and Vaxess developing skin patch mRNA vaccines for pandemic flu

23 Aug 2023

VaccinemRNA

AstraZeneca is developing a novel type of mRNA vaccine that can be administered as a shelf-stable skin patch instead of a shot, potentially making distribution and administration of pandemic vaccines easier, Endpoints News has learned. The pharmaceutical giant is partnering with Boston biotech startup Vaxess, which could get up to $10.3 million from AstraZeneca in a joint effort to develop prototype vaccines for pandemic influenza, Vaxess told Endpoints in an exclusive interview. Those funds are part of a larger award worth up to $80 million from the Department of Defense that AstraZeneca could use to develop and test the vaccine through a Phase I/II clinical study.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

AstraZeneca PLC

Vaxess Technologies, Inc.

Department of Defense Military Health System

Indications

Influenza, Human

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.